IMPORTANT LEGAL NOTICE - The information on this site is subject to adisclaimerand acopyright notice
 
Contact   |   Search  
Graphical element Graphical element Graphical element Graphical element Graphical element Graphical element Graphical element Graphical element Graphical element
Cell factory - Back to the homepage Graphic element Graphical element
Foreword Graphic element Graphical element
Table of contents Graphical element
Index by Index by Area Index by Partners Index by Keywords Graphic element Graphical element
Volume 2 Graphical element

a   |  b   |  c   |  d   |  e   |  f   |  g   |  h   |  i   |  j   |  k   |  l   |  m   |  n   |  o   |  p   |  q   |  r   |  s   |  t   |  u   |  v   |  w   |  x   |  y   |  z  |
Graphical element
 
parkin
  QLK3-2002-02114 European network to develop new therapeutic strategies for Parkinson's Disease using lentiviral vector technology ((N)EUROPARK)
 
pathogen inhibitors
  QLK3-2001-00305 Deoxyuridine triphosphate nucleotidohydrolase as drug target for the control of protozoal and bacterial infections (dUTPase)
 
periplasma
  QLK3-2002-02086 Exploiting the secretion machinery of Pseudomonas for the nanotechnological production of pharmaceuticals (NANOFOLDEX)
 
phage libraries
  QLK3-2001-00498 Therapeutic molecules for modulation of ligand-receptor mediated apoptosis (Triskel)
 
phagocytic activity
  QLK3-2002-02017 Clearance of apoptotic cells: Discovery of autoantigens and therapy for autoimmune diseases (APOCLEAR)
 
phenotypic differentiation
  QLK3-2002-01973 Developing single nucleotide polymorphism (SNP) markers for adaptive variation in forest trees (TREESNIPS)
 
phenotyping
  QLK3-2002-01772 Blood grouping and genotyping: Improving patient safety and blood transfusion compatibility (BloodGen)
 
phycology
  QLK3-2002-02132 Microalgae as cell factories for chemical and biochemical products (ALGINET)
 
physico-chemical gradients
  QLK3-2002-01938 Phototrophic biofilms and their potential applications: Towards the development of a unifying concept (PHOBIA)
 
physiopathology
  QLK3-2002-02136 Profiling metalloproteinase inhibition for tumour therapy
 
PKA anchoring
  QLK3-2002-02149 Anchored cAMP signaling implications for treatment of human disease (cAMP signalling)
 
PKS sequences
  QLK3-2002-01940 Eukaryotic polyketides in surrogate hosts (EUKETIDES)
 
plate-based bioassays
  QLK3-2002-01923 Biosensors for in situ evaluation of bioavailability of pollutants based on transcriptional regulators la carte (BIOCARTE)
 
pollutant measurement
  QLK3-2002-02063 Development and risk assessment of a field-based portable biosensor using genetically-modified bioluminescent bacteria (BIOGEM)
 
pollutants
  QLK3-2001-00101 Testing integrated GM-Rhizoremediation systems for soil bioremediation (GM-Rhizoremediation)
  QLK3-2001-00345 Molecular and engineering approach to anaerobic degradation of recalcitrant xenobiotic compounds: In situ removal of nitro- and aminoaromatic chemicals (MADOX)
 
polymorphism
  QLK3-2002-01772 Blood grouping and genotyping: Improving patient safety and blood transfusion compatibility (BloodGen)
 
process bottlenecks
  QLK3-2001-00403 Whole-cell Baeyer-Villiger monooxygenase biocatalysts: Methodologies for exploitation (BIOMEX)
 
process modelling
  QLK3-2001-00403 Whole-cell Baeyer-Villiger monooxygenase biocatalysts: Methodologies for exploitation (BIOMEX)
 
production analysis
  QLK3-2001-00403 Whole-cell Baeyer-Villiger monooxygenase biocatalysts: Methodologies for exploitation (BIOMEX)
 
prokaryotes
  QLK3-2002-01972 Multigenome access technology for industrial catalysts (MGAtech)
 
prokaryotic regulators
  QLK3-2002-01923 Biosensors for in situ evaluation of bioavailability of pollutants based on transcriptional regulators la carte (BIOCARTE)
 
proteases
  QLK3-2002-02136 Profiling metalloproteinase inhibition for tumour therapy
 
protein folding
  QLK3-2002-02086 Exploiting the secretion machinery of Pseudomonas for the nanotechnological production of pharmaceuticals (NANOFOLDEX)
 
protein/peptides
  QLK3-2001-00498 Therapeutic molecules for modulation of ligand-receptor mediated apoptosis (Triskel)
 
PrP-inhibitors
  QLK3-2001-00283 Integrated in vitro and in vivo testing of drugs in prion diseases: screening, development and mechanisms of novel therapeutics (STOPTSEs)
 
Pseudomas putida
  QLK3-2001-00435 Solvent tolerant bacteria allowing a broader performance of biotransformations of organic compounds in two phases (BARTOLO)
 
Pseudomonas aeruginosa
  QLK3-2001-00519 Directed evolution of enantioselective biocatalysts (EvoCatal)
Graphical element
a   |  b   |  c   |  d   |  e   |  f   |  g   |  h   |  i   |  j   |  k   |  l   |  m   |  n   |  o   |  p   |  q   |  r   |  s   |  t   |  u   |  v   |  w   |  x   |  y   |  z  |
Graphical element